Modifying risks of secondary leukemias: is drug scheduling important?
Karp
J E
JE
Smith
M A
MA
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004249:DNA Damage; D004273:DNA, Neoplasm; D004334:Drug Administration Schedule; D006801:Humans; D007938:Leukemia / Q000139:chemically induced* / Q000235:genetics; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000235:genetics; D016032:Randomized Controlled Trials as Topic; D012306:Risk
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm